Focused On-demand Library for Parathyroid hormone/parathyroid hormone-related peptide receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

PTH/PTHrP type I receptor; Parathyroid hormone 1 receptor

Alternative UPACC:

Q03431; Q2M1U3


The Parathyroid hormone/parathyroid hormone-related peptide receptor, also known as PTH/PTHrP type I receptor, plays a pivotal role in calcium homeostasis and bone metabolism. This receptor's activation by its ligands triggers crucial signaling pathways, including adenylyl cyclase and a phosphatidylinositol-calcium second messenger system, essential for maintaining calcium balance and bone development.

Therapeutic significance:

Linked to diseases such as Metaphyseal chondrodysplasia, Jansen type, Chondrodysplasia Blomstrand type, Eiken syndrome, and Primary failure of tooth eruption, the receptor's dysfunction underscores its therapeutic potential. Targeting the PTH/PTHrP receptor could lead to innovative treatments for these skeletal dysplasias and calcium homeostasis disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.